Objectives: Mycobacterium tuberculosis and Mycobacterium abscessus produce broad-spectrum class A b-lactamases, BlaC and Bla Mab , which are inhibited by clavulanate and avibactam, respectively. BlaC differs from Bla Mab at Ambler position 132 in the conserved motif SDN (SDG versus SDN, respectively). Here, we investigated whether this polymorphism could account for the inhibition specificity of b-lactamases from slowly and rapidly growing mycobacteria. G had opposite effects on the inhibition of BlaC and Bla Mab , indicating that these substitutions might lead to acquisition of resistance to either of the b-lactamase inhibitors, but not to both of them.
Introduction
The efficacy of b-lactams for the treatment of pulmonary infections due to mycobacteria is severely limited by the production of broad-spectrum Ambler class A b-lactamases combined with the very low permeability of the cell wall. [1] [2] [3] The b-lactamase BlaC produced by Mycobacterium tuberculosis is irreversibly inhibited by clavulanate, and the combination of clavulanate and meropenem (a carbapenem) is bactericidal in vitro and in cultured human macrophages. 4, 5 The combination is also uniformly active against extensively drug-resistant clinical isolates of M. tuberculosis. 5 Faropenem, an orally bioavailable b-lactam of the penem class approved in humans, has been shown to be superior to the frontline antituberculosis drug isoniazid in its ability to induce in vitro the rapid cytolysis of bacteria, including non-growing bacteria, which may be responsible for relapses. 6 These observations and limited clinical evaluations 7, 8 have been the basis for two Phase II clinical trials for evaluation of the early bactericidal activity of meropenem and faropenem in combination with clavulanate and amoxicillin. 9, 10 Recent results indicate that the viable mycobacterial sputum load was significantly reduced only for the combination containing meropenem. 10, 11 Mycobacterium abscessus is responsible for lung infections, especially in cystic fibrosis patients, which are treated by a combination of clarithromycin, amikacin and an intravenous b-lactam, either cefoxitin or imipenem. 12 The efficacy of the reference treatment is compromised by the inducible production of an rRNA methylase conferring clarithromycin resistance. 12 Cefoxitin and imipenem are used in the absence of a b-lactamase inhibitor since these drugs are slowly hydrolysed by the b-lactamase Bla Mab produced by M. abscessus. 13 Inhibition of Bla Mab by avibactam, a nonb-lactam b-lactamase inhibitor recently approved in humans (Figure 1 ), extends the spectrum of b-lactams active against M. abscessus in vitro, in cultured human macrophages and in a zebrafish model of acute infection. 3 In addition, avibactam may improve the activity of imipenem, but not that of cefoxitin, since only the former drug is slowly, but significantly, hydrolysed by Bla Mab . 14 We have previously shown that the motif SDN, which is highly conserved in class A b-lactamases, is replaced by the motif SDG in BlaC from M. tuberculosis and in all b-lactamases from slowly growing mycobacteria. 15 Substitution of glycine by asparagine at Ambler position 132 of BlaC (substitution G 132 N), which replaces the motif SDG by the conserved motif SDN present in most b-lactamases, abolishes inhibition of BlaC by clavulanate since the inhibitor is hydrolysed by the b-lactamase. 15 This observation raised the possibility of acquisition of resistance to the meropenem/clavulanate combination under treatment since the efficacy of the combination may be altered by a single mutation. 15 In contrast, amino acid substitutions affecting R 220 , A 244 , S 130 and T 237 of BlaC were not reported to lead to resistance to the ampicillin/clavulanate combination in M. tuberculosis since decreased interaction with the inhibitor occurred at the expense of a decrease in the catalytic activity of the b-lactamase.
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Since efficacious b-lactamase inhibition is instrumental to the development of improved b-lactam-based treatments of pulmonary infections due to mycobacteria, we have further evaluated in the current study the characteristics of mycobacterial b-lactamases that determine the efficacy of their inhibition by avibactam and clavulanate. We have extensively analysed the impact of the motifs SDN or SDG on the inhibition of class A b-lactamases from mycobacteria, including the impact of G 
Materials and methods
Production and purification of b-lactamases b-Lactamases were produced in Escherichia coli BL21 (DE3) (Invitrogen) harbouring recombinant plasmids that were obtained by cloning the b-lactamase genes into the vector pET-TEV, as previously described for the WT genes blaC and bla Mab . 13, 15 Synthetic genes encoding BlaC G 132 N and Bla Mab N 132 G were obtained from Genecust. Bacteria were grown in brain heart infusion broth (Difco) containing 50 mg/L kanamycin at 37 C to an OD 600 of 0.8, then IPTG (0.5 mM) was added, and cultures were further incubated for 18 h at 16 C. 13 The b-lactamases were purified from clarified lysates by affinity chromatography (Ni-NTA resin, Sigma-Aldrich) and size exclusion chromatography (Superdex 200 HL26/60 column, Amersham Pharmacia Biotech). 13 The purified b-lactamases were concentrated (10 mg/mL) by ultrafiltration (Amicon Ultra-4 centrifugal filter devices, Millipore) and stored at #65 C in 25 mM Tris-HCl (pH 7.5) containing 300 mM NaCl.
Determination of Bla Mab and BlaC kinetic parameters for b-lactams
The kinetic parameters k cat and K m were determined by spectrophotometry (Carry-100 Bio; Varian) in 100 mM MES (pH 6.4) at 20 C, as previously described. 4 The molar extinction coefficients for the b-lactams tested in this study are listed in Table S1 (available as Supplementary data at JAC Online). For hydrolysis of clavulanate by BlaC G 132 N, the value of K m was determined by analysing competitive hydrolysis of nitrocefin and clavulanate, as previously described. 17 The rate constants for carbamylation and decarbamylation of b-lactamases by avibactam were determined in 100 mM MES (pH 6.4) at 37 C, as previously described. 18 
MS analyses
Formation of drug-enzyme adducts was tested by incubating blactamases (10 lM) with b-lactams at 20 C in water. The reaction mixture was injected into the mass spectrometer (Qstar Pulsar I, Applied Biosystems) at a flow rate of 0.05 mL/min (acetonitrile 50%, water 49.5%, formic acid 0.5%; per volume). Spectra were acquired in the positive mode as previously described. 19 Heterospecific production of b-lactamases in E. coli and antibiotic susceptibility testing
In order to address the b-lactamases to the periplasm, the catalytic domains of Bla Mab (residues 22-289) and BlaC (41-307) were translationally fused to the signal sequence of the E. coli TorA protein and cloned under the control of pTRC promoter into the vector pTRC99k. 13 Expression of the b-lactamase genes was induced with IPTG (50 lM) and MICs of b-lactams were determined in Mueller-Hinton broth using the microdilution method in 96-well microplates, according to CLSI guidelines. Kanamycin (50 mg/L) was added to the growth medium throughout the experiments to counterselect the loss of pTRC99k derivatives encoding the b-lactamases.
Results

Impact of the substitution G 132 N on BlaC inhibition
Avibactam was previously shown to extensively inhibit BlaC from M. tuberculosis due to a very slow dissociation constant for the avibactam-BlaC adduct, although a low carbamylation rate was anticipated to preclude its use for the treatment of tuberculosis. 20 In this study, the chromogenic cephalosporin nitrocefin was used as a substrate to determine the impact of the substitution G Soroka et al.
b-lactamase ( Figure 2b ). The deduced efficacy of the carbamylation reaction (k 2 /K i ) was increased 140-fold from 63 + 2 to 8900 + 300 M #1 s #1 (Figure 2c ). In contrast, the impact of G 132 N on the decarbamylation rate was modest and marginally contributed to the stabilization of the covalent adduct since the rate constant k off was decreased 2.8-fold from 0.011 + 0.006 to 0.004 + 0.002 s #1 (Figure 2d ). Thus, the substitution G 132 N significantly increased the efficacy of BlaC inhibition by avibactam mainly due to an increase in the carbamylation rate (Table 1) . We have previously shown that the same substitution impaired the inhibition of BlaC by clavulanate. 15 BlaC was irreversibly inactivated by clavulanate, whereas BlaC G 132 N hydrolysed this drug. Thus, the G 132 N substitution had opposite effects on the efficacy of BlaC inhibition by avibactam and clavulanate.
Impact of the substitution N 132 G on Bla Mab inhibition
Bla Mab was previously shown to be efficaciously inhibited by avibactam with a carbamylation constant k 2 /K i of 1.
. 3 In contrast, Bla Mab is not inhibited by clavulanate since
. 3, 13 The N 132 G substitution led to a 610-fold reduction in the efficacy of Bla Mab carbamylation by avibactam (Table 1 and Figure S1 ). The N 132 G substitution also led to a 2500-fold reduction in the catalytic efficacy of clavulanate hydrolysis ( Table 2 ). The latter reduction was mainly due to a decrease in k cat (5600-fold), which was not compensated by the marginal (2-fold) decrease in K m (120 versus 54 lM). These results indicate that presence of N at position 132 of Bla Mab is critical both for efficacious inactivation of the b-lactamase by avibactam and for efficacious clavulanate hydrolysis.
The data presented in Tables 1 and 2 indicate that the substitutions at position 132 reduce the differences between BlaC and Bla Mab for all possible comparisons. For avibactam, the carbamylation constant k 2 /K i is 1700-fold lower for BlaC than for Bla Mab 5 nM) or BlaC G 132 N (2.5 nM) was incubated with nitrocefin (100 or 140 lM, respectively) and various concentrations of avibactam (100-600 or 0.5-10 lM, respectively). Equation (1) was fitted to progress curves in order to obtain the pseudo-first-order rate constant k obs . (c) Determination of carbamylation rate constant k 2 /K i . k obs was plotted as a function of the concentration of avibactam and Equation (2) was fitted to the data in order to deduce the value of the ratio k 2 /K i . (d) Kinetics of decarbamylation. BlaC (1 lM) or BlaC G 132 N (1 lM) was incubated with avibactam (50 and 5 lM, respectively) for 20 min. The mixture was diluted 10 000-fold and recovery of enzyme activity was measured using nitrocefin (100 lM) as the substrate. Equation (3) was fitted to progress curves to determine k off . Progress curves for uninhibited BlaC and BlaC G 132 N at the same concentrations are included.
Mycobacterial b-lactamase inhibition JAC was only 3-fold lower than that of Bla Mab . Finally, the N N is similar to Bla Mab (Tables 1 and 2 ), the distinctive behaviours of Bla Mab and BlaC with respect to the efficacy of their inhibition by avibactam and clavulanate are almost completely determined by the occurrence of N and G at position 132, respectively.
Inhibition of b-lactamases from slowly and rapidly growing mycobacteria
Phylogenetic analyses have previously shown that the genes encoding class A b-lactamases have been vertically inherited in mycobacteria. 15 Mycobacterium leprae is an exception since genome reductive evolution has included the b-lactamase gene. The b-lactamases from the two lineages encompassing the slowly and rapidly growing mycobacteria differ by the presence of G and N at position 132, respectively. b-Lactamases from representatives of the slowly growing (Mycobacterium marinum) and rapidly growing (Mycobacterium chelonae and Mycobacterium smegmatis) mycobacterial lineages were efficaciously inactivated only by clavulanate or only by avibactam, respectively (Tables 1 and 2 and Figure  S2) . Thus, the polymorphism at position 132 and the behaviour of the b-lactamases with respect to inhibition by clavulanate and avibactam both appear to be conserved in the two mycobacterial lineages. (Figure 3 ). Additional adducts with mass increases of 155 and 71 Da were detected, which may result from decarboxylation of clavulanate within the active site (þ155 Da) and subsequent hydrolysis of the imine bond generating the propionaldehyde (þ71 Da) (Figure 3b ), in agreement with previous analyses of the acylation of BlaC by clavulanate. 4, 21 The peaks corresponding to the acylenzyme (þ199 Da) were gradually replaced by those of the second adduct with a mass increase of 155 Da. Minor peaks corresponding to an acylenzyme with a mass increase of 71 Da were detected throughout the incubation. Steady-state hydrolysis of clavulanate by Bla Mab N 132 G (above; Table 2 ) occurred in conditions where the substantial majority of the enzyme molecules existed in the form of the adduct with a mass increment of 155 Da ($95%). Accumulation of this form of The kinetic constants k cat and K m for hydrolysis of a panel of 10 blactams by 7 b-lactamases were determined by spectrophotometry (Table S2 ). The relative catalytic efficacies were calculated for pairs of b-lactamases as presented in Figure 4 As previously described, 13 Bla Mab was more active than BlaC for hydrolysis of most b-lactams (Figure 4a ). The largest differences were observed for nitrocefin (83-fold) and for the carbapenems imipenem (33-fold) and meropenem (50-fold). The exceptions were cefoxitin, which was hydrolysed 1300-fold more efficaciously by BlaC than by Bla Mab , and ceftazidime with a minor 3.3-fold difference.
Substitution
Introduction of the substitution G 132 N in BlaC had marginal impacts (<2-fold; Figure 4b ) on the hydrolysis efficacy for amoxicillin (0.9-fold), cefalotin (1.2-fold), ceftaroline (0.6-fold), meropenem (1.5-fold) and faropenem (1.6-fold). The substitution significantly decreased the efficacy of hydrolysis of cefoxitin (27-fold) and ceftazidime (4.6-fold). In contrast, the substitution increased the efficacy of hydrolysis of nitrocefin (3.3-fold), imipenem (13-fold) and aztreonam (19-fold) . Overall, the substitution G 132 N was well tolerated by BlaC and altered the specificity of the enzyme, resulting in increasing similarities with the substrate profile of Bla Mab . The substitution N 132 G severely impaired the b-lactamase activity of Bla Mab for all b-lactams, except cefoxitin and ceftazidime (Figure 4c ).
In conclusion, the presence of N at position 132, corresponding to the SDN motif present in most b-lactamases, is essential for the optimum activity of Bla Mab . In contrast, G and N are both tolerated at position 132 of BlaC. In the context of the two enzymes, hydrolysis of nitrocefin, imipenem and aztreonam appears to be favoured by the presence of N at position 132. In BlaC, G at this position appears to have a favourable impact on the efficacy of hydrolysis of cefoxitin and ceftazidime.
Impact of the substitutions on the MICs of amoxicillin in combination with avibactam and clavulanate 
Discussion
b-Lactams remain the most broadly used family of antibiotics despite the emergence of multiple mechanisms of resistance. The discovery of b-lactamase inhibitors is a strategy of proven efficacy to extend the longevity and improve the activity of b-lactams. 22 The ultimate goal would be to obtain an inhibitor that is active for all b-lactamases. This is a challenging task due to the huge diversity of b-lactamases present in pathogenic bacteria and the even greater diversity potentially originating from modifications of their sequence and acquisition of previously unrecognized b-lactamase genes by horizontal transfer. An alternative approach would be to have access to a panel of inhibitors containing at least one inhibitor active for any single b-lactamase or combination of b-lactamases produced by any target pathogen. This approach would be costlier in terms of the need for susceptibility testing and more complicated in terms of decision making to select the appropriate therapeutic regimens, but could be as efficacious as a 'universal' inhibitor in terms of treatment outcome. So far, the ease with which bacteria might resist or gain resistance to a large panel of b-lactamase inhibitors combined with a large panel of b-lactams has been explored to a very limited extent. Indeed, only three inhibitors, clavulanate, tazobactam and sulbactam, have been widely used and those inhibitors have related modes of action, as they all belong to the b-lactam family. 22 With the approval of avibactam, and potentially of additional families of inhibitors with unrelated structures, such as the boronates, the diversity of the b-lactamase inhibitors continues to increase. 23, 24 The access to a greater diversity of inhibitors raises the question of whether a single b-lactamase can escape inhibition by a panel of molecules with truly distinct modes of action, while preserving sufficient activity for hydrolysis of the b-lactam partner of the inhibitor. Our study is relevant to this question since we have shown that the Table S1 for the complete set of data). In order to compare pairs of b-lactamases, the log 10 of the ratio of the catalytic efficiencies was plotted for each drug. (Tables 1 and 2 ) ( Figure 5 ). BlaC from M. tuberculosis, which carries a G at position 132, is irreversibly inactivated by clavulanate, and production of this enzyme in E. coli leads to resistance to amoxicillin, but not to the amoxicillin/clavulanate combination ( Table 3 ), indicating that inhibition of BlaC by clavulanate is efficacious, as previously observed in the original M. tuberculosis host. [4] [5] [6] The substitution G (Tables 1 and 2 ). Thus, the role of position 132 in determining efficacious inhibition by either clavulanate or avibactam, but not by both inhibitors, may be conserved in mycobacterial b-lactamases (Table 3) .
Efficacious inhibition of Bla Mab by avibactam (Table 1 ) led to amoxicillin susceptibility in E. coli (Table 3) , as previously reported for the M. abscessus host. 3 The substitution N 132 G in Bla Mab led to resistance to the amoxicillin/avibactam combination in the E. coli host. The parallel gain in the inactivation efficacy of Bla Mab by clavulanate due to N 132 G was associated with a large decrease in the MIC of the amoxicillin/clavulanate combination (from >512 to 32 mg/L). However, the MIC remained 16-fold higher than that of the E. coli host (2 mg/L) (Table S3) (Table S3) . Thus, although the substitution N 132 G in Bla Mab did not enable clavulanate to restore full susceptibility to amoxicillin, the impaired activity caused by N 132 G led to susceptibility to another drug. This observation illustrates the fact that treatment optimization should greatly benefit from the possibility of independently combining b-lactams and b-lactamase inhibitors. Unfortunately, b-lactamase inhibitors have been and continue to be developed as combinations. As a result, each inhibitor is available in combination with a very limited number ( 2) of b-lactam partners. The huge burden imposed by this development strategy can be exemplified by the limited options for the treatment of pulmonary infections due to M. abscessus. Avibactam efficaciously inhibits Bla Mab in vitro, in human macrophages and in zebrafish, 3 but the only approved formulation of avibactam (Zavicefta V R and Avicaz V R ) contains ceftazidime, which has no activity against the b-lactam targets in M. abscessus.
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Formulation of a b-lactamase inhibitor independently from a b-lactam partner would provide clinicians with an access to potentially useful therapeutic regimens based on combining approved b-lactams with approved inhibitors. Mycobacterial b-lactamase inhibition JAC
